Submit or Track your Manuscript LOG-IN
Latest Blogs: https://researcherslinks.com/en/kahoot-login/ https://researcherslinks.com/en/blooket-login/ https://researcherslinks.com/en/comcast-login/ https://researcherslinks.com/en/gimkit-login/

Advances in Immunotherapy Targeting Cancer with Next-Generation Checkpoint Inhibitors

Advances in Immunotherapy Targeting Cancer with Next-Generation Checkpoint Inhibitors

Riam Yousfe Muttair 

Department of Biology, College of Science, University of Thi-Qar, Iraq.

*Correspondence | Riam Yousfe Muttair, Department of Biology, College of Science, University of Thi-Qar, Iraq; Email: Riyam.yousef@sci.utq.edu.iq 

ABSTRACT

Immunotherapy does seem to be an adequate mention in the latest approach to cancer treatment, with checkpoint inhibitors substitute for the keys that open the immune system free against cancer cells. The paper covers the progress made in immunotherapy, highlighting next-stage checkpoint inhibitors as the vaccine which may turn today’s cancer treatment procedures into historical relics. The opening sentences describe historical background and the current going about the way of which immunotherapy is useful in modern oncology. The knowledge about cancer and immunotherapy also creates the doors leading us to the mechanism of the development of cancer cells as well as the immune system that can kill the cancer cells. Checkpoint inhibitors, the main pillars of the immunotherapy, are explored in a detailed manner taking into account some of the most important checkpoint pathways and their clinical implications. Next-generation checkpoint inhibitor is the same thing as opening new ways in which the success of cancer immunotherapy can be improved. Having done its best checks on the subtype of cells to be targeted, current algorithms and checkpoint inhibitors have been adopted to perfect preferences and specificities that address resistance mechanisms and immune-related adverse events. Advancing efficacy and safety profiles represents the core objective in the development of the new generation of inhibitors based on bi-specific antibodies, nanoparticle delivery systems, etc. The novel humanized next-generation checkpoint inhibitors demonstrate various antagonistic activity against multiple immune checkpoints as well as resistance mechanisms at the same time. It follows from here that these can offer a promising prospect of outcomes improvement as well minimization of off-target effects. These studies deliver the information about a growth of immunotherapy, and the production of the tumor microenvironment in the fight against cancer. 

To share on other social networks, click on any share button. What are these?

South Asian Journal of Life Sciences

December

S. Asian J. Life Sci., Vol. 12

Featuring

Click here for more

Subscribe Today

Receive free updates on new articles, opportunities and benefits


Subscribe Unsubscribe